Harold Bernstein Sells 16,142 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 16,142 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total value of $445,680.62. Following the completion of the transaction, the chief marketing officer directly owned 16,142 shares in the company, valued at approximately $445,680.62. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The shares were sold at an average price of $29.90, for a total transaction of $436,809.10.

Maze Therapeutics Price Performance

Shares of Maze Therapeutics stock opened at $27.18 on Friday. The company has a 50-day simple moving average of $27.79 and a two-hundred day simple moving average of $33.03. Maze Therapeutics, Inc. has a twelve month low of $12.81 and a twelve month high of $53.65. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -10.79 and a beta of 2.21. The company has a quick ratio of 17.88, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting analysts’ consensus estimates of ($0.76). Analysts forecast that Maze Therapeutics, Inc. will post -2.71 EPS for the current year.

Key Headlines Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: BTIG issued a Buy rating. The endorsement adds to the constructive analyst view of Maze’s pipeline and could support investor confidence. Maze Therapeutics Earns Buy Rating from BTIG Research
• Positive Sentiment: Maze strengthened its board with two experienced executives. Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., bring extensive clinical, pharmaceutical, partnering, and commercialization expertise. Management also highlighted additional MZE829 data in late 2026 or early 2027, initial MZE782 data in 2027, and additional trial starts next year. Maze Therapeutics Announces Appointments to Its Board of Directors
• Positive Sentiment: HC Wainwright raised all of its reported EPS forecasts. Estimates improved for third-quarter 2026, fourth-quarter 2026, and fiscal years 2026 through 2030. For example, FY2026 EPS was revised to a loss of $2.81 from $2.96, while FY2030 was revised to a loss of $0.72 from $0.74, indicating expectations for a somewhat faster reduction in losses over time.
• Neutral Sentiment: Maze reported second-quarter 2026 financial results and recent business highlights. The available report headline does not provide the detailed financial figures, so the earnings release’s impact cannot be fully assessed from the supplied information. Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
• Negative Sentiment: Maze remains unprofitable. HC Wainwright’s revised forecasts still call for substantial losses through 2030, and its FY2026 estimate of a $2.81 loss is slightly worse than the $2.73 consensus forecast.
• Negative Sentiment: Reported insider activity is a concern. Company insiders have recorded sales but no purchases during the past six months, potentially weighing on sentiment.

Wall Street Analyst Weigh In

Several brokerages have recently commented on MAZE. BTIG Research restated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Finally, Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and an average price target of $66.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Hhlr Advisors LTD. acquired a new stake in shares of Maze Therapeutics during the 2nd quarter valued at $10,922,000. Jupiter Topco LLC bought a new stake in Maze Therapeutics during the 2nd quarter worth $101,764,000. ARCH Venture Management LLC acquired a new position in Maze Therapeutics in the 2nd quarter worth about $122,983,582,000. ADAR1 Capital Management LLC acquired a new position in Maze Therapeutics in the 2nd quarter worth about $10,124,000. Finally, Canada Pension Plan Investment Board bought a new position in Maze Therapeutics in the second quarter valued at about $272,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.